000 | 01376nam a2200133Ia 4500 | ||
---|---|---|---|
008 | 220620s9999||||xx |||||||||||||| ||und|| | ||
020 | _a9783040000000 | ||
245 | 0 | _aPharmacogenetics to Avoid Adverse Drug Reactions | |
546 | _aEnglish[eng] | ||
650 | _a5-fluorouracil||capecitabine||fluoropyrimidine||thymidylate synthase||thymidylate synthase enhancer region||upstream stimulatory factor 1||adverse drug reactions||pharmacogenomics||epistasis||random forest||statin||cardiovascular disease||colorectal cancer||personalised medicine||toxicity||(es)citalopram||drug-gene-interaction||drug-drug-interaction||drug-drug-gene-interaction||the PharmLines initiative||antipsychotic agents||pharmacogenetics||cytochrome P-450 enzyme system||psychotic disorders||precision medicine||direct oral anticoagulants||clinical implementation||atorvastatin||SLCO1B1||HLA||cutaneous adverse drug reaction||SCAR||genetic polymorphism||antiepileptics||CYP450 enzymes||platelet reactivity||single-nucleotide variants||acute coronary syndrome||clopidogrel||genotype||allele||polymorphism||HLA B||CYP2C9*3||cutaneous adverse drug reactions (CADRs)||anti-epileptic drugs (AEDS)||phenytoin (PHT)||genetic risk factors||South India||India||cardiology||adverse events||guidelines||n/a | ||
700 | _aLópez-Fernández, Luis A. | ||
856 | _uhttps://mdpi.com/books/pdfview/book/5039 | ||
942 | _cEB | ||
999 |
_c31262 _d31262 |